Latest News

Companies and People

The Myelin Repair Foundation Welcomes University of California, San Francisco’s Dr Jonah Chan to its Research Consortium The Myelin Repair Foundation Welcomes University of California, San Francisco’s Dr Jonah Chan to its Research Consortium

The Myelin Repair Foundation (MRF) today announced the newest member of its research consortium, Dr. Jonah Chan, Associate Professor of Neurology from University of California, San Francisco. As a sponsored researcher, Dr Chan joins 40 MRF principal investigators and researchers in the consortium focused on advancing myelin repair science for multiple sclerosis (MS).
11 May 2012

Label-Free Technologies Conference: New Webcast Label-Free Technologies Conference: New Webcast

The Label-Free Technologies conference in Amsterdam, Netherlands, on 1-3 November 2012, brings together the latest research on the advances and application of label-free technology in pharmacology and drug discovery.
03 May 2012

Supreme Court clears the way for generic patent challenges Supreme Court clears the way for generic patent challenges

The United States Supreme Court this week handed down another decision affecting patent law in biotechnology. The case decided this week will have an immediate impact on the makers of generic and branded pharmaceuticals.
24 April 2012

BioCity Scotland Dragons’ Den prize worth £10,000 BioCity Scotland Dragons’ Den prize worth £10,000

BioCity Scotland, the centre for life science businesses in Newhouse, Lanarkshire, will award a prize worth £10,000 at this year’s BioEntrepreneur Boot Camp Scotland, a three-day intensive business development programme designed to prepare scientists to be their own boss.
02 April 2012

£10 million boost for neglected tropical disease research at Dundee £10 million boost for neglected tropical disease research at Dundee

The University of Dundee has received over £10 million from the Wellcome Trust in the fight against some of the world’s most neglected parasitic diseases, including support for a multi-million pound partnership with GlaxoSmithKline (GSK) to discover new drug treatments.
06 March 2012

Takara Bio Europe offers real-time PCR training webinars in collaboration with world-class provider, TATAA Biocenter Takara Bio Europe offers real-time PCR training webinars in collaboration with world-class provider, TATAA Biocenter

Takara Bio Europe today announced that it has joined forces with leading qPCR training provider TATAA Biocenter to offer free educational webinars in real-time PCR (qPCR) for academic and industrial researchers and laboratory technicians.
21 February 2012

Xceleron announces new investment and move to purpose-built laboratories in USA Xceleron announces new investment and move to purpose-built laboratories in USA

Xceleron, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, announced that existing investors Albion Ventures and Solon Ventures have invested US$2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.
16 February 2012

GSK injects $60 million and 58 jobs into Victoria GSK injects $60 million and 58 jobs into Victoria

GlaxoSmithKline Pty Ltd (GSK) announced that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria, Australia. The investment by one of the world’s leading pharmaceutical companies will create 58 new highly-skilled jobs by 2017.
08 February 2012

OGT founder Professor Sir Ed Southern awarded the 2011 MRC Millennium Medal OGT founder Professor Sir Ed Southern awarded the 2011 MRC Millennium Medal

Professor Sir Ed Southern, founder of Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has been awarded the 2011 Medical Research Council (MRC) Millennium Medal.
30 January 2012

Charity bids to rid Africa of blinding disease Charity bids to rid Africa of blinding disease

Development charity Sightsavers has today unveiled a 10-year campaign to help eliminate one of the world’s leading causes of preventable blindness, termed onchocerciasis (also river blindness). With plans to fundraise and invest more than £27 million over the next decade to help combat this neglected tropical disease (NTD) across Africa, the charity is starting work this month in the Democratic Republic of the Congo where the disease is endemic.
17 January 2012

New cluster for life sciences as BioCity Scotland secures a future for MSD Newhouse site New cluster for life sciences as BioCity Scotland secures a future for MSD Newhouse site

BioCity Scotland Ltd, a joint venture between BioCity Nottingham and Roslin BioCentre, has today announced the acquisition of the former-MSD research facility at Newhouse, Lanarkshire. This exciting deal will enable the development of a dedicated base in central Scotland for growing bioscience, pharmaceutical, med tech and healthcare companies.
11 January 2012

UK Biobank: launch of procedures for accessing the resource UK Biobank: launch of procedures for accessing the resource

UK Biobank launches its Access Procedures today (Wednesday 14th), which govern the way the resource can be used by scientists to improve the health of future generations.
14 December 2011

Government UK life sciences strategy a significant step forward Government UK life sciences strategy a significant step forward

The BioIndustry Association (BIA) welcomes the Prime Minister's announcement of a coordinated life sciences strategy which could provide a foundation for the future of the bioscience sector in the UK
14 December 2011

Drug Discovery Oxford 2012 Drug Discovery Oxford 2012

The Drug Discovery Oxford 2012 – “Drug discovery: a job too complex for academia or industry alone?” conference is only a month away.
05 December 2011

Horizon 2020: A new research framework for developing and sharing knowledge Horizon 2020: A new research framework for developing and sharing knowledge

The European Federation of Pharmaceutical Industries and Associations (EFPIA), the voice of the research-based pharmaceutical industry in Europe, welcomes the launch of the European Commission’s new Framework for Research and Innovation: Horizon 2020.
01 December 2011

Cambridge-Elan centre for research innovation and drug discovery launched Cambridge-Elan centre for research innovation and drug discovery launched

The University of Cambridge and Elan Corporation plc today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England.
28 November 2011

Celgene marks UK expansion with opening of new headquarters Celgene marks UK expansion with opening of new headquarters

Celgene, one of the world’s largest developers of biopharmaceuticals has demonstrated its commitment to UK expansion with the opening of its new London headquarters, accommodating its growing numbers of UK staff and the Celgene global regulatory and drug safety teams.
23 November 2011

Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors

Actelion Ltd announced that Jean-Pierre Garnier has become Chairman of the Board of Directors of the Swiss biopharmaceutical company. The Board of Directors elected him at their meeting today, 27 September 2011. To ensure a smooth transition, Robert Cawthorn, who has been Chairman since the inception of the company, will stay on the Board as planned until the 2012 Annual General Meeting.
30 September 2011

Gilead licence expands access, but several countries left out Gilead licence expands access, but several countries left out

An agreement announced today by pharmaceutical company Gilead to licence several HIV/AIDS drugs to the Medicines Patent Pool could improve access to medicines for patients. However, this agreement excludes several countries with large numbers of people living with HIV, the international medical humanitarian organisation Médecins Sans Frontières (MSF) said today.
12 July 2011

Government to invest in new research to tackle threat caused by sepsis Government to invest in new research to tackle threat caused by sepsis

The Technology Strategy Board and the Department of Health are to invest up to £7.5 million in new research and development that aims to improve the future diagnosis, detection and management of sepsis, a life-threatening illness caused by the body overreacting to an infection.
05 July 2011

Showing 1 - 20 of 115 articles